Metformin in nonalcoholic steatohepatitis: a randomized controlled trial

Area of Science:

• Hepatology
• Metabolic Disorders
• Clinical Trials

Background:

• Nonalcoholic steatohepatitis (NASH) is a progressive liver disease linked to insulin resistance.
• Metformin, an insulin-sensitizing drug, is explored for NASH treatment.
• NASH affects an estimated 3% of the Iranian population.

Purpose of the Study:

• To evaluate metformin's efficacy in improving biochemical and histological markers in NASH patients.
• To compare metformin's effects against a placebo in a randomized controlled trial.

Main Methods:

• A 6-month randomized double-blind controlled trial involving 33 biopsy-proven NASH patients.
• Participants received either metformin (500 mg twice daily) or a placebo.
• Liver enzymes (AST, ALT) were monitored, and weight loss was encouraged.

Main Results:

• Both metformin and placebo groups showed significant decreases in AST and ALT levels.
• The magnitude of liver enzyme reduction was not significantly different between the groups.
• Weight loss was identified as the main factor contributing to biochemical improvements.

Conclusions:

• Metformin did not demonstrate a significant effect on liver enzyme levels in NASH patients.
• Observed improvements in liver enzymes were primarily attributed to weight loss.
• Further research may be needed to clarify metformin's role in NASH management.